Abstract:Inhibitors of DNA methyltransferase (DNMTs) are now a major family of epigenetic targets with therapeutic interest. However, only two cytosine analogues 5-azacytosine (azacytidine) and 20-deoxy-5-azacytidine (decitabine), have been approved as the most cutting-edge medications for treating epigenetic cancer with some restrictions. In this context, computational methods that rely on quantitative structure-activity relationship (QSAR) play a crucial role allowing us to predict the biological activity of potential molecules based on the theoretically calculated physicochemical properties of these compounds. When coupled with machine learning (ML), QSAR approaches create an ideal platform for discovering potential drug candidates. In this study, three Machine Learning (ML) models; Random Forest, Support Vector Machine, and Artificial Neural Network, were trained using modified TeachOpenCADD KNIME workflows and applied it to the identification of plant molecules that are structurally similar to the active pharmaceuticals of current DNMT inhibitors. Then molecular docking simulations were performed using AutoDock Vina, employing two human DNMT structures (PDB codes: 4WXX and 2QRV) as target proteins and the predicted phytochemicals as ligands. Additionally, we focused on the R882H mutation hotspot in the catalytic domain of DNMT3A, which is associated with aberrant DNA methylation in acute myeloid leukemia (AML). Consequently, the structure of R882H DNMT3A (PDB code: 6W8J) was docked with the identified novel ligands. As a result of our computational analysis, eight phytochemicals were predicted as potential DNMT inhibitors through the ML approaches from KNIME. Subsequently, three of these phytochemicals, namely Herbacetin, Kaempferide, and Morin were identified as virtual hits against DNMTs following the molecular docking simulations. Overall, our study demonstrates the effectiveness of this computational strategy in identifying DNMT inhibitors. These findings hold promise for the discovery of potent and selective anticancer drugs targeting DNMTs.

Insights into the Inhibitory Mechanisms of the Covalent Drugs for DNMT3A

Unveiling the methyl transfer mechanisms in the epigenetic machinery DNMT3A-3 L: A comprehensive study integrating assembly dynamics with catalytic reactions

Insight into the Selective Binding Mechanism of DNMT1 and DNMT3A Inhibitors: a Molecular Simulation Study.

Dnmt1 Mediates Chemosensitivity By Reducing Methylation Of Mirna-20a Promoter In Glioma Cells

DNA Methyltransferase Inhibitors and Their Therapeutic Potential

Abstract 1397: the Regulation of DNMT3B Expression by Lncrna-Ncrms in Cancer

DNA Methyltransferase Inhibitors and Their Therapeutic Potential.

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Targeting DNA methyltransferases for cancer therapy

Insights into Conformational Dynamics and Allostery in DNMT1-H3Ub/USP7 Interactions

Prediction of the binding mechanism of a selective DNA methyltransferase 3A inhibitor by molecular simulation

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Z-DNA as a Tool for Nuclease-Free DNA Methyltransferase Assay

Computer-aided drug design to discover DNMT inhibitors from phytochemicals

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches

Natural bioactive compounds targeting DNA methyltransferase enzymes in cancer: Mechanisms insights and efficiencies

Structural View on the Role of the TRD Loop in Regulating DNMT3A Activity: a Molecular Dynamics Study.

Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors Through Docking-Based Virtual Screening.